The anti-obesity drugs are they dangerous long-term Canadian study highlights the lack of available data on the health impact of existing anti-obesity drugs. The study their effects on weight loss is modest, and several adverse effects were observed…

According to a study published in the medical journal The Lancet, the drug against obesity must still show that the bene fice their overall health is to provide superior long-term potential risks that may cause their catch.

Priority. While three drugs against obesity are marketed or about to be, several side effects were observed. These drugs against obesity are orlistat (brand name Xenical), sibutramine (trade name Sibutral) and rimonabant (trade name Acomplia).

Thus, orlistat reduces the progression of diabetes in patients at high risk, but it would present gastrointestinal side effects. For its part, in addition to insomnia, nausea and other constipation, sibutramine would increase the tension. Rimonabant promote the good cholesterol but may cause nausea, dizziness, diarrhea and mental disorders.

News Daily news and environmental sustainability and health: more than 22,000 subscribers receive the free weekly News Letter of the environment. More than 3.5 million unique visitors in 2009.


.